Daniel Cohen is the founder and CEO of ZModal.
He previously founded and served as CEO of 3DBio Therapeutics, where he led the first FDA IND for a 3D-printed living tissue, advancing into a Phase I/IIa clinical trial—work featured on the front page of the New York Times and awarded Health Innovation of the Year by Popular Science.
A three-time Cornell alumnus with a PhD in mechanical engineering, he began his career at McKinsey & Co., advising Fortune 500 technology and manufacturing clients.
At ZModal, he leverages this experience to build the infrastructure required for real-time, model-driven biomanufacturing.
Daniel is a mechanical and biomedical engineer and a serial deep-tech entrepreneur dedicated to bringing regulated, high-risk technologies from concept to production.
As the founder of 3DBio Therapeutics, he secured the first FDA approval for implanting 3D-printed living tissue — a milestone featured on the front page of The New York Times and honored with Popular Science’s Grand Award. During the COVID-19 pandemic, he also led the development and federal approval of advanced respiratory protection systems under extreme pressure.
A three-time Cornell alumnus holding undergraduate and PhD degrees in engineering, Daniel has earned fellowships from the NSF and the U.S. Department of Homeland Security. His expertise spans bioprocess instrumentation and regulated manufacturing where physics, biology, and compliance intersect.
At ZModal, he leverages this experience to build the infrastructure required for real-time, model-driven biomanufacturing.
